ArticleJournal of translational medicine2026
COL10A1
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbdominal aortic aneurysm (AAA) rupture remains the leading cause of AAA-related mortality, while current clinical management relies primarily on aneurysm diameter, which inadequately predicts rupture risk. Increasing evidence suggests that stromal cell heterogeneity critically shapes vascular remodeling; however, the specific fibroblast states associated with AAA rupture predisposition remain poorly defined.
methodsWe integrated cross-species single-cell RNA-sequencing datasets spanning the full spectrum of AAA progression to systematically characterize fibroblast heterogeneity and state transitions. Pseudotime trajectory analysis, transcriptional regulatory network inference, and ligand-receptor interaction modeling were applied to delineate fibroblast-associated microenvironmental programs. Based on these findings, a fibroblast-derived molecular signature was constructed and validated in an independent human AAA cohort.
resultsSingle-cell analysis revealed a progressive transition from homeostatic IGFBP6
conclusionsThis study identifies a COL10A1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.